513 assets in Ovarian Cancer

Therapeutic assets addressing Ovarian Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Famitinib Ovarian Cancer	Jinhua Zhou	P3	B (58)
Gm-Csf Ovarian Cancer	Georgetown University	P2	B (58)
hs-20089 Ovarian Cancer	Jiangsu Hansoh Pharmaceutical Co., Ltd.	P3	B (58)
Letrozole Ovarian Cancer	Peking Union Medical College Hospital	P3	B (58)
Pamiparib Ovarian Cancer	Sun Yat-sen University	P3	B (58)
Pertuzumab Ovarian Cancer	OHSU Knight Cancer Institute	P3	B (58)
Prednisolone Ovarian Cancer	AstraZeneca	P2	B (58)
Tamoxifen Ovarian Cancer	OHSU Knight Cancer Institute	P3	B (58)
Trastuzumab Deruxtecan Ovarian Cancer	Yonsei University	P3	B (58)
Vinorelbine Ditartrate Ovarian Cancer	OHSU Knight Cancer Institute	P3	B (58)
Cediranib Ovarian Cancer	Yonsei University	P3	B (57)
Fulvestrant Ovarian Cancer	Terremoto Biosciences Inc.	P2	B (57)
GEH300079 (68Ga) Ovarian Cancer	GE Healthcare	P2/3	B (57)
Olvimulogene Nanivacirepvec Ovarian Cancer	Genelux Corporation	P3	B (57)
Talazoparib Ovarian Cancer	Alexander B Olawaiye, MD	P3	B (57)
Tiaoshen Anti-Cancer Granules Ovarian Cancer	Shanghai Municipal Hospital of Traditional Chinese Medicine	P2/3	B (57)
Adebrelimab Ovarian Cancer	Obstetrics & Gynecology Hospital of Fudan University	P2/3	B (56)
Cetuximab Ovarian Cancer	Fate Therapeutics	P2	B (56)
Diphenhydramine Ovarian Cancer	Merck Sharp & Dohme LLC	P3	B (56)
Eribulin Ovarian Cancer	Second Affiliated Hospital of Guangzhou Medical University	P2	B (56)
Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer Ovarian Cancer	Yonsei University	P2	B (56)
Palbociclib Ovarian Cancer	Bristol-Myers Squibb	P2	B (56)
Prednisone Ovarian Cancer	AstraZeneca	P2	B (56)
Rituximab Ovarian Cancer	M.D. Anderson Cancer Center	P2	B (56)
Sodium Thiosulfate Ovarian Cancer	National Cancer Center, Korea	P3	B (56)
Tranexamic Acid Ovarian Cancer	Sheikh Zayed Medical College	P4	B (56)
Trastuzumab Ovarian Cancer	Fate Therapeutics	P2	B (56)
Anastrozole Ovarian Cancer	OHSU Knight Cancer Institute	P2	CCC (55)
Com 701 Ovarian Cancer	Compugen Ltd	P1/2	CCC (55)
Dostarlimab Ovarian Cancer	AGO Research GmbH	P3	CCC (55)
Enzalutamide Ovarian Cancer	Nuvation Bio Inc.	P2	CCC (55)
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer Ovarian Cancer	Regeneron Pharmaceuticals	P2	CCC (55)
Ipilimumab Ovarian Cancer	Regeneron Pharmaceuticals	P2	CCC (55)
Nemvaleukin Ovarian Cancer	Mural Oncology, Inc	P3	CCC (55)
Upifitamab Rilsodotin Ovarian Cancer	Mersana Therapeutics	P1/2	CCC (55)
Alpelisib Ovarian Cancer	OHSU Knight Cancer Institute	P3	CCC (54)
Benmelstobart Ovarian Cancer	Second Affiliated Hospital, School of Medicine, Zhejiang University	P3	CCC (54)
Bleomycin Ovarian Cancer	Beihua Kong	P3	CCC (54)
Decitabine Ovarian Cancer	University of Chicago	P2/3	CCC (54)
Defactinib Ovarian Cancer	Verastem, Inc.	P2	CCC (54)
Immunoglobulin G1, Anti-(Human Epidermal Growth Factor Receptor Her2) (Human-Mus Musculus Monoclonal Shr-1805 ?1-Chain), Complex With Human-Mus Musculus Monoclonal Shr-1805 ?-Chain, Dimer, Thioether With N-[6-(3-Mercapto-2,5-Dioxo-1-Pyrrolidinyl)-1-Oxohexyl]Glycylglycyl-L-Phenylalanyl-N-[[(1R)-1-Cyclopropyl-2-[[(1S,9S)-9-Ethyl-5-Fluoro-2,3,9,10,13,15-Hexahydro-9-Hydroxy-4-Methyl-10,13-Dioxo-1H,12H-Benzo[De]Pyrano[3?,4?:6,7]Indolizino[1,2-B]Quinolin-1-Yl]Amino]-2-Oxoethoxy]Methyl]Glycinamide Ovarian Cancer	Tongji Hospital	P3	CCC (54)
Imnn-001 Ovarian Cancer	Imunon	P3	CCC (54)
Incb123667 Ovarian Cancer	Incyte Corporation	P3	CCC (54)
Navicixizumab Ovarian Cancer	OncXerna Theraputics, Inc.	P3	CCC (54)
Propofol Ovarian Cancer	Kaohsiung Medical University Chung-Ho Memorial Hospital	P4	CCC (54)
Sacituzumab Tirumotecan Ovarian Cancer	Merck Sharp & Dohme LLC	P3	CCC (54)
Sevoflurane Ovarian Cancer	Kaohsiung Medical University Chung-Ho Memorial Hospital	P4	CCC (54)
Shr-A1921 Ovarian Cancer	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	P3	CCC (54)
Adsorbed Purified Pertussis Vaccine Ovarian Cancer	Mayo Clinic	P2	CCC (53)
Ast-201 Ovarian Cancer	Aston Sci. Inc.	P2	CCC (53)

Showing 51 to 100 of 513 assets

PreviousPage 2 of 11Next